TJM Labs, a pharmacy AI platform automating operational workflows for pharmacies, has disclosed $100 million raised across three funding rounds completed in approximately six months: a $10 million Series A, a $15 million Series A-1 and a $75 million Series B led by Elephant, with participation from Arthur Ventures and Updata Partners.
Alongside the funding disclosure, the Wilmington, Delaware-based company announced it is now live in more than 450 pharmacies and has completed two acquisitions—EncoreRx and Pharmesol—adding automation and voice capabilities to build out a single pharmacy-native platform.
TJM Labs’ AI agents automate the repetitive operational work that consumes pharmacy staff time: prescription intake, data entry, refill processing, prior authorization support and patient communication, all operating across the systems pharmacy teams already use rather than requiring rip-and-replace infrastructure changes. The company says its agents process more than 500,000 pharmacy tasks every day, giving it a scale of deployment that its backers argue moves it from pilot-stage product to production infrastructure. The announcement is framed as a deliberate shift from “quiet operator” to visible category leader as the pharmacy AI market moves beyond point solutions toward enterprise-scale platforms.
A defining characteristic of TJM Labs is its pharmacy-native founding. CEO Jonathan Adly worked as a pharmacist for 15 years before founding the company, and the platform was built with pharmacists and AI engineers working side by side throughout development. This expertise is codified in the company’s Dual-Expert Model, which pairs pharmacists with AI engineers on every deployment to ensure automation is designed around real pharmacy workflows, operational complexity and pharmacist oversight. The model is intended to address a common failure point in healthcare automation: systems built by engineers without sufficient clinical context that break down under the practical conditions of pharmacy operations.
The two acquisitions extend TJM Labs’ platform in complementary directions. EncoreRx brings additional automation capabilities, while Pharmesol adds voice-based interaction tools, together broadening the range of workflows the platform can handle and deepening its integration into pharmacy operating environments. The acquisitions form part of a consolidation strategy as the pharmacy AI market fragments between point solutions and more comprehensive platforms: TJM is positioning itself as the destination for pharmacies that want to unify AI automation under one vendor rather than managing multiple disconnected tools.
TJM Labs has demonstrated scale across a wide range of pharmacy segments, including retail, specialty, compounding, long-term care, mail order, central fill and enterprise multi-location operations. The platform’s design philosophy is to reallocate labor rather than replace clinical judgment: by reducing the repetitive manual work that drives staff burnout and operational bottlenecks, it aims to free pharmacists and technicians to spend more time on patient care. Backers highlight that TJM’s combination of pharmacy-native expertise, deployed agents processing millions of tasks annually and measurable customer outcomes gives it a leadership position in a category transitioning from experimentation to infrastructure.
KEY QUOTES:
“Pharmacy AI is no longer theoretical — it is already running in hundreds of pharmacies. We built TJM Labs to automate the real operational work that slows pharmacy teams down, and we’ve done it with pharmacists and engineers working side by side. With AI agents processing more than 500,000 pharmacy tasks every day across 450+ pharmacies and $100 million raised, we’re accelerating the platform pharmacies already rely on.”
Jonathan Adly, Founder and CEO, TJM Labs
“TJM Labs has built what pharmacy AI companies are still pitching: a production platform already running inside hundreds of pharmacies processing millions of tasks annually. The company’s combination of pharmacy-native expertise, deployed AI agents, and measurable customer outcomes gives it a clear leadership position in a category moving from experimentation to infrastructure.”
Jeremiah Daly, General Partner, Elephant
“TJM Labs has been a game changer for our pharmacy. In a highly regulated environment where automation and AI aren’t easy to implement, their experience and thoughtful approach made all the difference. We already have a strong tech stack, and TJM helped us truly leverage it by designing AI agents that fit our workflows, reduce manual work, and let our teams focus more on patient care. The impact has been immediate and meaningful across our operations. Their team is responsive, knowledgeable, and transparent. They genuinely feel like an extension of our team.”
Ann Olaguer, Senior Director, Data Strategy and IT, Valor Compounding Pharmacy
